7 Related NICE guidance
-
Ofatumumab for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab. NICE technology appraisal guidance 202 (2010).
-
Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia. NICE technology appraisal guidance 193 (2010).
-
Rituximab for the first-line treatment of chronic lymphocytic leukaemia. NICE technology appraisal guidance 174 (2009).
-
Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukemia. NICE technology appraisal guidance 119 (2007).
-
Improving outcomes in haematological cancers. NICE cancer service guidance (2003).